Teva Pharmaceutical Industries Investor Presentation — March 2021

Document content

Teva Pharmaceutical Industries Ltd.

J.P. Morgan 2021 Global High Yield &

Leveraged Finance Conference

Executive Vice President, Chief Financial Officer March 2, 2021Cautionary Note Regarding Forward- Looking Statements

This presentation contains forw ard- looking statements w ithin the meaning of the Private Securities Litigation Reform Act of 1995, w hich are based on management ’s current beliefs and expectations and are subject to

substantial risks and uncertainties, both know n and unknow n, that could cause our future results, performance or achievements todiffer significantly from that expressed or implied by such forw ard- looking statements.

Important factors that could cause or contribute to such differences include risks relating to:

•our ability to successfully compete in the marketplace, including: that w e are substantially dependent on our generic products; c onsolidation of our customer base and commercial alliances among our customers; delays in

launches of new generic products; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; our ability to develop and

commercialize biopharmaceutical products; competition for our specialty products, including AUSTEDO®, AJOVY®and COPAXONE®; our ability to achieve expected results from investments in our product pipeline; our

ability to develop and commercialize additional pharmaceutical products; and the effectiveness of our patents and other measures to protect our intellectual property rights;

•our substantial indebtedness, w hich may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further dow ngrade of our credit ratings; and our

inability to raise debt or borrow funds in amounts or on terms that are favorable to us;

•our business and operations in general, including: uncertainty regarding the magnitude, duration, and geographic reach of the COV ID-19 pandemic and its impact on our business, financial condition, operations, cash

flow s, and liquidity and on the economy in general; our ability to successfully execute and maintain the activities and effor ts related to the measures w e have taken or may take in response to the COVID -19 pandemic and

associated costs therew ith; effectiveness of our optimization efforts; our ability to attract, hire and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions of

information technology systems; breaches of our data security; variations in intellectual property law s; challenges associated w ith conducting business globally, including political or economic instability, major hostilities or